Clinical Trial

Phase Ib Study of HS-20093+HRS-5041 in Patients With Advanced Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
HS-20093 is a fully humanized IgG1 antibody-drug conjugate (ADC) which specifically binds to B7-H3, a target wildly expressed on solid tumor cells. HRS-5041 is a Proteolysis Targeting Chimeras (PROTAC) targeting androgen receptors. This is a phase Ib, open-label, multi-center study to evaluate the safety, tolerability, and pharmacokinetics (PK) of HS-20093 combination with HRS-5041 in patients with advanced prostate cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-04.
Status change: Not Yet Recruiting → Recruiting 2025-11-28
Trial Details
NCT Number NCT07115446
Lead Sponsor Hansoh BioMedical R&D Company
Conditions Advanced Prostate Cancer
Enrollment 63 participants
Start Date 2025-08-19
Primary Completion 2027-12 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-05